|
1.
|
Downward J: Ras signalling and apoptosis.
Curr Opin Genet Dev. 8:49–54. 1998. View Article : Google Scholar
|
|
2.
|
Barbacid M: Ras genes. Annu Rev Biochem.
56:779–827. 1987. View Article : Google Scholar
|
|
3.
|
Kiaris H and Spandidos D: Mutations of
ras genes in human tumours (Review). Int J Oncol. 7:413–421.
1995.
|
|
4.
|
Downward J: Targeting RAS signalling
pathways in cancer therapy. Nat Rev Cancer. 3:11–22. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Fang JY and Richardson BC: The MAPK
signalling pathways and colorectal cancer. Lancet Oncol. 6:322–327.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Chong H, Vikis HG and Guan K-L: Mechanisms
of regulating the Raf kinase family. Cell Signal. 15:463–469. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Storm SM, Brennscheidt U, Sithanandam G
and Rapp UR: Raf oncogenes in carcinogenesis. Crit Rev Oncog.
2:1–8. 1990.
|
|
8.
|
Davies H, Bignell GR, Cox C, et al:
Mutations of the BRAF gene in human cancer. Nature. 417:949–954.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Mikula M, Schreiber M, Husak Z, et al:
Embryonic lethality and fetal liver apoptosis in mice lacking the
c-raf-1 gene. EMBO J. 20:1952–1962. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Wojnowski L, Zimmer AM, Beck TW, et al:
Endothelial apoptosis in Braf-deficient mice. Nat Genet.
16:293–297. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Wojnowski L, Stancato LF, Larner AC, Rapp
UR and Zimmer A: Overlapping and specific functions of Braf and
Craf-1 proto-oncogenes during mouse embryogenesis. Mech Dev.
91:97–104. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Rajagopalan H, Bardelli A, Lengauer C,
Kinzler KW, Vogelstein B and Velculescu VE: Tumorigenesis: RAF/RAS
oncogenes and mismatch-repair status. Nature. 418:9342002.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Britten RA, Perdue S, Opoku J and
Craighead P: paclitaxel is preferentially cytotoxic to human
cervical tumor cells with low Raf-1 kinase activity: implications
for paclitaxel-based chemoradiation regimens. Radiother Oncol.
48:329–334. 1998. View Article : Google Scholar
|
|
14.
|
Rasouli-Nia A, Liu D, Perdue S and Britten
RA: High Raf-1 kinase activity protects human tumor cells against
paclitaxel-induced cytotoxicity. Clin Cancer Res. 4:1111–1116.
1998.PubMed/NCBI
|
|
15.
|
Huser M, Luckett J, Chiloeches A, et al:
MEK kinase activity is not necessary for Raf-1 function. EMBO J.
20:1940–1951. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Murakami MS and Morrison DK: Raf-1 without
MEK? Sci STKE. 2001:e302001.
|
|
17.
|
Nowell PC: The clonal evolution of tumor
cell populations. Science. 194:23–28. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Kinzler KW and Vogelstein B: Landscaping
the cancer terrain. Science. 280:1036–1037. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Jain M, Arvanitis C, Chu K, et al:
Sustained loss of a neoplastic phenotype by brief inactivation of
MYC. Science. 297:102–104. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Felsher DW and Bishop JM: Reversible
tumorigenesis by MYC in hematopoietic lineages. Mol Cell.
4:199–207. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Pelengaris S, Littlewood T, Khan M, Elia G
and Evan G: Reversible activation of c-Myc in skin: induction of a
complex neoplastic phenotype by a single oncogenic lesion. Mol
Cell. 3:565–577. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Chin L, Tam A, Pomerantz J, Wong M, et al:
Essential role for oncogenic Ras in tumour maintenance. Nature.
400:468–472. 1999. View
Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Barbacid M: Ras oncogenes: their role in
neoplasia. Eur J Clin Invest. 20:225–235. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Anderson P: Kinase cascades regulating
entry into apoptosis. Microbiol Mol Biol Rev. 61:33–46.
1997.PubMed/NCBI
|
|
25.
|
Rice PL, Goldberg RJ, Ray EC, Driggers LJ
and Ahnen DJ: Inhibition of extracellular signal-regulated kinase
1/2 phosphorylation and induction of apoptosis by sulindac
metabolites. Cancer Res. 61:1541–1547. 2001.PubMed/NCBI
|
|
26.
|
Bos JL, Fearon ER, Hamilton SR, et al:
Prevalence of ras gene mutations in human colorectal cancers.
Nature. 327:293–297. 1987. View
Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Zhou G and Kuo MT: NF-κB-mediated
induction of mdr1b expression by insulin in rat hepatoma cells. J
Biol Chem. 272:15174–15183. 1997.
|
|
28.
|
Zimmermann S, Rommel C, Ziogas A, Lovric
J, Moelling K and Radziwill G: MEK1 mediates a positive feedback on
Raf-1 activity independently of Ras and Src. Oncogene.
15:1503–1511. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Harding A, Giles N, Burgess A, Hancock JF
and Gabrielli BG: Mechanism of mitosis-specific activation of MEK1.
J Biol Chem. 278:16747–16754. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
30.
|
Ley R, Balmanno K, Hadfield K, Weston C
and Cook SJ: Activation of the ERK1/2 signaling pathway promotes
phosphorylation and proteasome-dependent degradation of the
BH3-only protein. Bim. J Biol Chem. 278:18811–18816. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Sebolt-Leopold JS, Dudley DT, Herrera R,
et al: Blockade of the MAP kinase pathway suppresses growth of
colon tumors in vivo. Nat Med. 5:810–816. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Majewski M, Nieborowska-Skorska M,
Salomoni P, et al: Activation of mitochondrial Raf-1 is involved in
the antiapoptotic effects of Akt. Cancer Res. 59:2815–2819.
1999.PubMed/NCBI
|
|
33.
|
Fang X, Yu S, Eder A, et al: Regulation of
BAD phosphorylation at serine 112 by the Rasmitogen-activated
protein kinase pathway. Oncogene. 18:6635–6640. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34.
|
Zhong J, Troppmair J and Rapp UR:
Independent control of cell survival by Raf-1 and Bcl-2 at the
mitochondria. Oncogene. 20:4807–4816. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Subramanian RR, Masters SC, Zhang H and Fu
H: Functional conservation of 14-3-3 isoforms in inhibiting
bad-induced apoptosis. Exp Cell Res. 271:142–151. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36.
|
Chen J, Fujii K, Zhang L, Roberts T and Fu
H: Raf-1 promotes cell survival by antagonizing apoptosis
signal-regulating kinase 1 through a MEK-ERK independent mechanism.
Proc Natl Acad Sci USA. 98:7783–7788. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Baumann B, Weber CK, Troppmair J, et al:
Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling
pathway critical for transformation. Proc Natl Acad Sci USA.
97:4615–4620. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
38.
|
Alessandrini A, Greulich H, Huang W and
Erikson RL: Mek1 phosphorylation site mutants activate Raf-1 in NIH
3T3 cells. J Biol Chem. 271:31612–31618. 1996. View Article : Google Scholar : PubMed/NCBI
|
